Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Efficacy of Sequential Intravesical Gemcitabine and Docetaxel Therapy (GEM/DOCE) in High-risk BCG-naive Patients With Non-muscle Invasive Bladder Cancer (NMIBC)

NCT05671900 is registered in ClinicalTrials.gov with Clinical Hospital Centre Zagreb as lead sponsor.

NCT NCT05671900
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05671900 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Efficacy of Sequential Intravesical Gemcitabine and Docetaxel Therapy (GEM/DOCE) in High-risk BCG-naive Patients With Non-muscle Invasive Bladder Cancer (NMIBC)
Lead sponsor
Clinical Hospital Centre Zagreb
Phase
Not applicable
Overall status
Unknown status
Start date
April 1, 2020
Completion date
December 31, 2024
Enrollment
70 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non-muscle-invasive bladder cancer